Protein Engineering and Structural Characterisation Approaches Aimed Towards the Improvement of Biological Therapies
Year: 2019
Type: dissertation
Abstract: Biological therapies are currently at the forefront of pharmaceutical innovation and drug discovery. Seminal developments in molecular biology and recombinant technologies in the 1990’s brought about a new era in biomedicine, inasmuch as they expanded the ability to manipulate the synthetic machinery of biological systems for the production of recombinant macromolecules with exquisite therapeutic potential and versatility. Most prominent among these developments were advances in the manufacture of humanised and human monoclonal antibodies in a streamlined fashion. Biotherapeutics then experienced a remarkable boom in the early 2000’s and currently remain the fastest-growing class of therapeutics. As the field of molecular biology continues to advance at an accelerated pace, manifold opportunities are presented to implement new tools and technologies in the design of novel biotherapeutics and the refinement of existing biological therapies. The empirical research contained in this thesis reports on various approaches to address crucial aspects of the development of novel biotherapeutics, and demonstrates the application of modern mass spectrometry methods to gain insight into the complex structural features of macromolecules. Three main aims were defined and addressed in this work. The first aim consisted in employing a tailored mass spectrometry method to acquire the site-specific glycan profile of an influenza surface glycoprotein that plays a crucial role in infectivity and antigenicity. The structural data obtained sheds light into antigenic properties of the virus that can aid in the design of recombinant vaccines. The second aim sought to evaluate a protein engineering strategy to improve the biophysical properties of monoclonal antibodies through the targeted insertion of glycosylation sites in strategic positions on the protein. The data reported demonstrates the capabilities of the technique to increase physical stability and underlines aspects that require further refinement moving forward. The final aim focused on the synthesis of a nanoparticle-based drug delivery platform that employs antibodies as targeting agents for increased treatment specificity. We demonstrated the feasibility of chemically modifying the antibody using concomitant protein functionalisation techniques to produce antibody-drug conjugates that bind to the surface of gold nanoparticles to serve as targeting agents. The synthesized nanocarrier is designed to accumulate preferentially in tumours through the enhanced permeability and retention effect, where it can subsequently engage in specific interactions with tumour cells via active-targeting of the antibody. Altogether, the body of work presented in this thesis reports on novel experimental approaches that will aid in the design and production of next-generation biotherapeutics.
Author: Esteban Cruz
Institution: The University of Sydney
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2999190282
